19552
Overview
Inflammatory bowel disease (IBD) remains a major unmet medical need, with current therapies relying on chronic immunosuppression rather than restoring immune tolerance. We identified naturally occurring intestinal MHC Class II peptides derived from intestinal stem cells that promote regulatory T cell (Treg) expansion and immune tolerance, supporting their development as immune tolerance-inducing therapeutics for IBD.
In addition, inflammation-specific damage-associated peptides were identified as potential therapeutic targets for controlling pathogenic immune activation during IBD flares.
Applications
- Immune tolerance-inducing therapies for Crohn's disease and ulcerative colitis
- Prevention of disease flares through targeting inflammation-associated peptides
Differentiation
Targets intestinal immune pathways without broad immunosuppression
Enables both tolerance restoration and anti-inflammation
Development Stage
- Lead intestinal stem cell-derived MHC-II peptides identified through in vivo immunopeptidomics
- In vivo mouse studies demonstrated Treg expansion and increased IL-10 production following immunization with stem cell-derived peptides
- Damage-associated MHC-II peptides identified in the DSS colitis mouse model
Reference
Contact for more information
